

Curis to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

CAMBRIDGE, Mass., Oct 31, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced that the Company will be presenting at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, which is being held on November 5-7, 2007 at the Palace Hotel in New York, New York. Curis' presentation will take place on Tuesday, November 6, 2007 at 4:05 p.m. Eastern Standard Time.

Daniel R. Passeri, MSc., J.D., Curis' President and CEO, will provide a presentation that includes an overview of the status of Curis' business, including CUDC-101 and the other proprietary small molecule cancer programs under Curis' Targeted Cancer Drug Development Platform. There will also be a corresponding webcast of the presentation, which can be accessed by visiting: <http://www.wsw.com/webcast/rrshq12/cris>

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease. For more information, visit www.curis.com.

SOURCE: Curis, Inc.

Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com

<https://investors.curis.com/Curis-to-Present-at-Acumen-BioFin-Rodman-Renshaw-9th-Annual-Healthcare-Conference>